Board Change • Jul 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Non-Executive Non-Independent Director Upendar Reddy was the last director to join the board, commencing their role in 2023. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jun 23
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to ₹177, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 65% over the past three years. Announcement • Jun 22
Bafna Pharmaceuticals Limited Announces Board and Committee Changes Bafna Pharmaceuticals Limited informed that Mr. Navin Kumar (DIN: 08778662) will be retiring as an Independent Director of the Company upon completion of his first term, with effect from close of business hours on June 22, 2026. Consequently, he also ceased to be the Chairman of the Audit Committee and the Nomination & Remuneration Committee of the Company. The following Committees of the Board of Directors have been re-constituted with effect from June 23, 2026: Audit Committee: Mr. Palamadai Krishnan Sundaresan, Chairman (Non-Executive, Independent); Mrs. Ravichandran Chitra, Member (Non-Executive, Independent); Mr. Upendar Mekala Reddy, Member (Non-Executive, Non-Independent). Nomination and Remuneration Committee: Mr. Palamadai Krishnan Sundaresan, Chairman (Non-Executive, Independent); Mrs. Ravichandran Chitra, Member (Non-Executive, Independent); Mrs. Akila Chintalapati Raju, Member (Non-Executive, Non-Independent). The composition of the Board and its Committees continues to remain in compliance with the requirements of the applicable laws. New Risk • Jun 08
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Market cap is less than US$100m (₹4.59b market cap, or US$48.2m). Valuation Update With 7 Day Price Move • Jun 05
Investor sentiment improves as stock rises 34% After last week's 34% share price gain to ₹176, the stock trades at a trailing P/E ratio of 37.6x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 42% over the past three years. Reported Earnings • May 31
Full year 2026 earnings released: EPS: ₹4.69 (vs ₹1.76 in FY 2025) Full year 2026 results: EPS: ₹4.69 (up from ₹1.76 in FY 2025). Revenue: ₹1.55b (up 6.5% from FY 2025). Net income: ₹111.0m (up 167% from FY 2025). Profit margin: 7.1% (up from 2.8% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings. Announcement • May 21
Bafna Pharmaceuticals Limited to Report Q4, 2026 Results on May 29, 2026 Bafna Pharmaceuticals Limited announced that they will report Q4, 2026 results on May 29, 2026 Valuation Update With 7 Day Price Move • Apr 09
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹136, the stock trades at a trailing P/E ratio of 33.3x. Average trailing P/E is 27x in the Pharmaceuticals industry in India. Total returns to shareholders of 53% over the past three years. Valuation Update With 7 Day Price Move • Mar 19
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹121, the stock trades at a trailing P/E ratio of 29.5x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 41% over the past three years. Reported Earnings • Feb 13
Third quarter 2026 earnings released: EPS: ₹0.78 (vs ₹0.40 in 3Q 2025) Third quarter 2026 results: EPS: ₹0.78 (up from ₹0.40 in 3Q 2025). Revenue: ₹395.1m (up 19% from 3Q 2025). Net income: ₹18.4m (up 94% from 3Q 2025). Profit margin: 4.6% (up from 2.9% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Announcement • Feb 05
Bafna Pharmaceuticals Limited to Report Q3, 2026 Results on Feb 11, 2026 Bafna Pharmaceuticals Limited announced that they will report Q3, 2026 results on Feb 11, 2026 New Risk • Jan 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 9.5% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Market cap is less than US$100m (₹2.78b market cap, or US$30.3m). Valuation Update With 7 Day Price Move • Dec 23
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹165, the stock trades at a trailing P/E ratio of 44.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 62% over the past three years. Reported Earnings • Nov 17
Second quarter 2026 earnings released: EPS: ₹1.32 (vs ₹1.11 in 2Q 2025) Second quarter 2026 results: EPS: ₹1.32 (up from ₹1.11 in 2Q 2025). Revenue: ₹354.7m (down 12% from 2Q 2025). Net income: ₹31.2m (up 19% from 2Q 2025). Profit margin: 8.8% (up from 6.5% in 2Q 2025). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 21% per year, which means it is well ahead of earnings. Announcement • Nov 08
Bafna Pharmaceuticals Limited to Report Q2, 2026 Results on Nov 11, 2025 Bafna Pharmaceuticals Limited announced that they will report Q2, 2026 results on Nov 11, 2025 Valuation Update With 7 Day Price Move • Nov 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹158, the stock trades at a trailing P/E ratio of 45.3x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 51% over the past three years. Valuation Update With 7 Day Price Move • Sep 29
Investor sentiment improves as stock rises 22% After last week's 22% share price gain to ₹176, the stock trades at a trailing P/E ratio of 50.5x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 72% over the past three years. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹117, the stock trades at a trailing P/E ratio of 33.5x. Average trailing P/E is 31x in the Pharmaceuticals industry in India. Total returns to shareholders of 12% over the past three years. New Risk • Aug 20
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.4% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Market cap is less than US$100m (₹2.45b market cap, or US$28.2m). Valuation Update With 7 Day Price Move • Aug 19
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹109, the stock trades at a trailing P/E ratio of 31.2x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total loss to shareholders of 5.7% over the past three years. Announcement • Aug 13
Bafna Pharmaceuticals Limited, Annual General Meeting, Sep 19, 2025 Bafna Pharmaceuticals Limited, Annual General Meeting, Sep 19, 2025, at 10:00 Indian Standard Time. Reported Earnings • Aug 13
First quarter 2026 earnings released: EPS: ₹1.43 (vs ₹0.31 loss in 1Q 2025) First quarter 2026 results: EPS: ₹1.43 (up from ₹0.31 loss in 1Q 2025). Revenue: ₹352.2m (up 5.8% from 1Q 2025). Net income: ₹33.9m (up ₹41.1m from 1Q 2025). Profit margin: 9.6% (up from net loss in 1Q 2025). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Announcement • Aug 09
Bafna Pharmaceuticals Limited to Report Q1, 2026 Results on Aug 12, 2025 Bafna Pharmaceuticals Limited announced that they will report Q1, 2026 results on Aug 12, 2025 Valuation Update With 7 Day Price Move • Jul 02
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹91.20, the stock trades at a trailing P/E ratio of 51.9x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total loss to shareholders of 21% over the past three years. Reported Earnings • Feb 08
Third quarter 2025 earnings released: EPS: ₹0.40 (vs ₹1.24 loss in 3Q 2024) Third quarter 2025 results: EPS: ₹0.40 (up from ₹1.24 loss in 3Q 2024). Revenue: ₹333.8m (up 17% from 3Q 2024). Net income: ₹9.48m (up ₹38.9m from 3Q 2024). Profit margin: 2.8% (up from net loss in 3Q 2024). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings. Reported Earnings • Nov 12
Second quarter 2025 earnings released: EPS: ₹1.11 (vs ₹1.05 in 2Q 2024) Second quarter 2025 results: EPS: ₹1.11 (up from ₹1.05 in 2Q 2024). Revenue: ₹413.5m (up 1.6% from 2Q 2024). Net income: ₹26.2m (up 5.4% from 2Q 2024). Profit margin: 6.3% (up from 6.1% in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 18% per year, which means it is performing significantly worse than earnings. Announcement • Aug 13
Bafna Pharmaceuticals Limited, Annual General Meeting, Sep 25, 2024 Bafna Pharmaceuticals Limited, Annual General Meeting, Sep 25, 2024, at 10:30 Indian Standard Time. Announcement • Aug 07
Bafna Pharmaceuticals Limited to Report Q1, 2025 Results on Aug 13, 2024 Bafna Pharmaceuticals Limited announced that they will report Q1, 2025 results on Aug 13, 2024 Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹87.36, the stock trades at a trailing P/E ratio of 28.1x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total loss to shareholders of 37% over the past three years. Announcement • May 30
Bafna Pharmaceuticals Limited Approves the Appointment of A. Mohanachandran as Company Secretary and Compliance Officer The Board of Directors of Bafna Pharmaceuticals Limited in their meeting held on May 29, 2024 approved the appointment of Mr. A. Mohanachandran, as the Company Secretary & Compliance Officer of the Company with effect from May 29, 2024. Mr. Mohanachandran, is a qualified CompanySecretary and an Associate Member of Institute of Company Secretaries of India with ICSI Membership No. A65827. He has 4 years of Post-Qualification Experience. Announcement • May 24
Bafna Pharmaceuticals Limited to Report Q4, 2024 Results on May 29, 2024 Bafna Pharmaceuticals Limited announced that they will report Q4, 2024 results on May 29, 2024 Valuation Update With 7 Day Price Move • May 03
Investor sentiment improves as stock rises 21% After last week's 21% share price gain to ₹104, the stock trades at a trailing P/E ratio of 21.9x. Average trailing P/E is 34x in the Pharmaceuticals industry in India. Total loss to shareholders of 29% over the past three years. Valuation Update With 7 Day Price Move • Apr 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹91.85, the stock trades at a trailing P/E ratio of 19.3x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total loss to shareholders of 36% over the past three years. Reported Earnings • Nov 14
Second quarter 2024 earnings released: EPS: ₹1.05 (vs ₹0.68 in 2Q 2023) Second quarter 2024 results: EPS: ₹1.05 (up from ₹0.68 in 2Q 2023). Revenue: ₹406.8m (up 85% from 2Q 2023). Net income: ₹24.8m (up 54% from 2Q 2023). Profit margin: 6.1% (down from 7.3% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 26% per year, which means it is significantly lagging earnings. Announcement • Oct 31
Bafna Pharmaceuticals Limited to Report Q2, 2024 Results on Nov 09, 2023 Bafna Pharmaceuticals Limited announced that they will report Q2, 2024 results on Nov 09, 2023 Valuation Update With 7 Day Price Move • Oct 05
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹96.40, the stock trades at a trailing P/E ratio of 14x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 82% over the past three years. Announcement • Sep 24
Bafna Pharmaceuticals Limited Announces Resignation of Kamlesh Kumar Babulal as Non-Executive Independent Director from the Board Bafna Pharmaceuticals Limited announced that Kamlesh Kumar Babulal resigned as Non-Executive Independent Director from the Board of the Company with immediate effect on personal grounds. Shri Kamlesh Kumar Babulal was also the Chairman of the Nomination and Remuneration Committee and Member of Audit Committee and Corporate Social Responsibility Committee of the Company. Date of cessation is September 9, 2023, after office hours. Reported Earnings • Aug 17
First quarter 2024 earnings released: EPS: ₹2.68 (vs ₹0.57 in 1Q 2023) First quarter 2024 results: EPS: ₹2.68 (up from ₹0.57 in 1Q 2023). Revenue: ₹419.5m (up 148% from 1Q 2023). Net income: ₹63.5m (up 366% from 1Q 2023). Profit margin: 15% (up from 8.0% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 66% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹103, the stock trades at a trailing P/E ratio of 21.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 338% over the past three years. Announcement • Aug 12
Bafna Pharmaceuticals Limited, Annual General Meeting, Sep 22, 2023 Bafna Pharmaceuticals Limited, Annual General Meeting, Sep 22, 2023, at 10:25 Indian Standard Time. Announcement • Aug 04
Bafna Pharmaceuticals Limited to Report Q1, 2024 Results on Aug 11, 2023 Bafna Pharmaceuticals Limited announced that they will report Q1, 2024 results on Aug 11, 2023 Board Change • Jul 12
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Additional Non-Executive Non-Independent Director Upendar Reddy was the last director to join the board, commencing their role in 2023. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Valuation Update With 7 Day Price Move • Jun 03
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to ₹119, the stock trades at a trailing P/E ratio of 24.7x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 483% over the past three years. Reported Earnings • May 30
Full year 2023 earnings released: EPS: ₹4.86 (vs ₹2.17 in FY 2022) Full year 2023 results: EPS: ₹4.86 (up from ₹2.17 in FY 2022). Revenue: ₹1.19b (up 39% from FY 2022). Net income: ₹113.4m (up 120% from FY 2022). Profit margin: 9.6% (up from 6.1% in FY 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth. Announcement • May 17
Bafna Pharmaceuticals Limited to Report Q4, 2023 Results on May 24, 2023 Bafna Pharmaceuticals Limited announced that they will report Q4, 2023 results on May 24, 2023 Reported Earnings • Feb 09
Third quarter 2023 earnings released: EPS: ₹1.26 (vs ₹0.72 in 3Q 2022) Third quarter 2023 results: EPS: ₹1.26 (up from ₹0.72 in 3Q 2022). Revenue: ₹342.2m (up 67% from 3Q 2022). Net income: ₹29.9m (up 76% from 3Q 2022). Profit margin: 8.8% (up from 8.3% in 3Q 2022). The increase in margin was driven by higher revenue. Announcement • Feb 01
Bafna Pharmaceuticals Limited to Report Q3, 2023 Results on Feb 08, 2023 Bafna Pharmaceuticals Limited announced that they will report Q3, 2023 results on Feb 08, 2023 Announcement • Jan 20
Bafna Pharmaceuticals Limited Announces Resignation of Atul Sachdeva as Director Bafna Pharmaceuticals Limited announced Mr. Atul Sachdeva (DIN: 07645130), Non-Executive Non Independent Director has resigned from the Board of the Company vide his resignation letter dated 13th January 2023 due to preoccupation. The letter as received by the Company is enclosed herewith as Annexure A. Accordingly, Mr. Atul Sachdeva ceased to be an Non Executive Non Independent Director from the Board of the Company effective 13th January, 2023. Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹0.68 (vs ₹0.95 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.68 (down from ₹0.95 in 2Q 2022). Revenue: ₹226.0m (down 21% from 2Q 2022). Net income: ₹16.1m (down 32% from 2Q 2022). Profit margin: 7.1% (down from 8.4% in 2Q 2022). The decrease in margin was driven by lower revenue. Board Change • Nov 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive & Independent Director Babulal Kumar is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 13
Second quarter 2023 earnings released: EPS: ₹0.68 (vs ₹0.95 in 2Q 2022) Second quarter 2023 results: EPS: ₹0.68 (down from ₹0.95 in 2Q 2022). Revenue: ₹226.0m (down 21% from 2Q 2022). Net income: ₹16.1m (down 32% from 2Q 2022). Profit margin: 7.1% (down from 8.4% in 2Q 2022). The decrease in margin was driven by lower revenue. Reported Earnings • Aug 12
First quarter 2023 earnings released: EPS: ₹0.57 (vs ₹0.88 in 1Q 2022) First quarter 2023 results: EPS: ₹0.57 (down from ₹0.88 in 1Q 2022). Revenue: ₹182.3m (down 14% from 1Q 2022). Net income: ₹13.6m (down 35% from 1Q 2022). Profit margin: 7.5% (down from 9.8% in 1Q 2022). Reported Earnings • Jul 07
Full year 2022 earnings released: EPS: ₹2.17 (vs ₹2.46 in FY 2021) Full year 2022 results: EPS: ₹2.17 (down from ₹2.46 in FY 2021). Revenue: ₹851.4m (up 20% from FY 2021). Net income: ₹51.5m (down 12% from FY 2021). Profit margin: 6.1% (down from 8.2% in FY 2021). Post-clinical trial products Pre-registration: 220 Reported Earnings • May 30
Full year 2022 earnings released: EPS: ₹2.17 (vs ₹2.46 in FY 2021) Full year 2022 results: EPS: ₹2.17 (down from ₹2.46 in FY 2021). Revenue: ₹872.4m (up 23% from FY 2021). Net income: ₹51.5m (down 12% from FY 2021). Profit margin: 5.9% (down from 8.2% in FY 2021). Board Change • Apr 27
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. 1 experienced director. No highly experienced directors. Non-Executive Independent Director Babulal Kumar is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improved over the past week After last week's 15% share price gain to ₹136, the stock trades at a trailing P/E ratio of 37.4x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total loss to shareholders of 7.1% over the past year. Reported Earnings • Feb 13
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹0.72 (up from ₹0.38 in 3Q 2021). Revenue: ₹204.6m (up 17% from 3Q 2021). Net income: ₹17.0m (up 89% from 3Q 2021). Profit margin: 8.3% (up from 5.2% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment improved over the past week After last week's 27% share price gain to ₹153, the stock trades at a trailing P/E ratio of 41.3x. Average trailing P/E is 25x in the Pharmaceuticals industry in India. Total loss to shareholders of 9.9% over the past year. Valuation Update With 7 Day Price Move • Dec 10
Investor sentiment improved over the past week After last week's 19% share price gain to ₹146, the stock trades at a trailing P/E ratio of 39.8x. Average trailing P/E is 23x in the Pharmaceuticals industry in India. Total loss to shareholders of 22% over the past year. Reported Earnings • Nov 15
Second quarter 2022 earnings released: EPS ₹0.95 (vs ₹0.20 in 2Q 2021) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: ₹286.2m (up 88% from 2Q 2021). Net income: ₹23.8m (up 396% from 2Q 2021). Profit margin: 8.3% (up from 3.1% in 2Q 2021). The increase in margin was driven by higher revenue. Valuation Update With 7 Day Price Move • Jul 16
Investor sentiment improved over the past week After last week's 17% share price gain to ₹163, the stock trades at a trailing P/E ratio of 66.8x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 629% over the past year. Reported Earnings • Jun 29
Full year 2021 earnings released: EPS ₹2.46 (vs ₹9.17 loss in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹719.7m (up 69% from FY 2020). Net income: ₹58.3m (up ₹80.0m from FY 2020). Profit margin: 8.1% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Is New 90 Day High Low • Feb 02
New 90-day low: ₹123 The company is down 8.0% from its price of ₹134 on 04 November 2020. The Indian market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 6.0% over the same period. Is New 90 Day High Low • Dec 16
New 90-day high: ₹202 The company is up 681% from its price of ₹25.85 on 16 September 2020. The Indian market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 7.0% over the same period. Valuation Update With 7 Day Price Move • Nov 23
Market pulls back on stock over the past week After last week's 17% share price decline to ₹164, the stock is trading at a trailing P/E ratio of 8.2x, down from the previous P/E ratio of 9.8x. This compares to an average P/E of 22x in the Pharmaceuticals industry in India. Is New 90 Day High Low • Oct 13
New 90-day high: ₹58.50 The company is up 161% from its price of ₹22.40 on 13 July 2020. The Indian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 18% over the same period.